Taysha Gene Therapies, Inc. Stock Analysis & AI Score
Taysha Gene Therapies, Inc. (TSHA) has an ST Score of 49.1 (C+), driven by its Forecast (A) and held back by its Growth (C-). Analysts rate it Buy with a $14.00 price target (+192.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Taysha Gene Therapies, Inc. (TSHA) has an ST Score of 49.1 (C+), driven by its Forecast (A) and held back by its Growth (C-). Analysts rate it Buy with a $14.00 price target (+192.3% upside).
- Strongest
- ForecastA
- Weakest
- GrowthC-
All factor grades
- ForecastA
- Financial StrengthB
- ProfitabilityB-
- MomentumC+
- ValuationC
- GrowthC-
- Piotroski2/9
Contact
TSHA stock: frequently asked questions
What is TSHA's ST Score?
Taysha Gene Therapies, Inc. (TSHA) has an ST Score of 49.1 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TSHA a buy, hold, or sell?
Analysts rate TSHA a Buy, with a price target of $14.00 (+192.3% vs the current price). Our ST Score grades it C+ (49.1/100). The ST Score is a data-driven signal, not a recommendation.
What are TSHA's factor grades?
Valuation C, Profitability B-, Financial Strength B, Momentum C+, Growth C-, Forecast A.
What is TSHA's valuation grade?
Taysha Gene Therapies, Inc. (TSHA) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TSHA's growth grade?
Taysha Gene Therapies, Inc. (TSHA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TSHA's profitability grade?
Taysha Gene Therapies, Inc. (TSHA) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TSHA's financial strength grade?
Taysha Gene Therapies, Inc. (TSHA) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TSHA?
The average analyst price target for Taysha Gene Therapies, Inc. (TSHA) is $14.00 from 18 analysts, which is +192.3% versus the recent price of $4.79.
What is TSHA's Piotroski score?
Taysha Gene Therapies, Inc. (TSHA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.